-
MK-5108 (VX-689) in Aurora A Assays
2026-09-10
MK-5108 (VX-689) is a highly selective Aurora A inhibitor for connecting kinase biology with cell-cycle, cancer cell line, and xenograft workflows. Its strong biochemical potency and lower Aurora B/C activity make it useful for mechanism-focused experiments, provided solubility, vehicle exposure, and pathway-specific controls are managed carefully.
-
Ziprasidone Hydrochloride: Assay Workflows
2026-09-10
A scenario-based guide to using Ziprasidone Hydrochloride (SKU A5350) in viability, proliferation, apoptosis, migration, and Caco-2 permeability workflows. It connects product handling data with published nanocrystal permeability findings while separating formulation effects from biological activity.
-
L-Alanyl-L-Glutamine: Protocol and QC Guide
2026-09-09
L-Alanyl-L-Glutamine provides a water-soluble L-Ala-L-Gln dipeptide format for workflows examining intestinal mucosa protection, barrier-related endpoints, and nutritional support under controlled conditions. It should be prepared in water rather than DMSO or ethanol, with fresh working solutions used because long-term aqueous storage is not recommended.
-
Bacitracin B1670: Practical Research Guide
2026-09-09
Bacitracin B1670 is a peptide antibiotic for controlled antibacterial research involving bacterial cell wall and peptidoglycan synthesis disruption. This guide covers preparation, controls, solubility, storage, and interpretation boundaries; the product is not intended for diagnostic, clinical, or medical use.
-
ARCA EGFP mRNA (5-moUTP): Assay Confidence
2026-09-08
ARCA EGFP mRNA (5-moUTP) enables direct, fluorescence-based assessment of mRNA delivery and expression in mammalian cells. This article connects cap chemistry, modified uridine, polyadenylation, storage science, and measurement uncertainty to improve assay interpretation.
-
Magnetite-Coated CNCs for Magnetic Hyperthermia
2026-09-08
This study connects cellulose nanocrystal surface chemistry with magnetite binding, colloidal behavior, magnetic response, and hyperthermia heating. Its comparative design shows how sulfated and TEMPO-oxidized interfaces produce different trade-offs between adsorption strength, magnetic retention, heating efficiency, and preliminary biocompatibility.
-
Alternariol Workflows for Mycotoxin Research
2026-09-07
Alternariol (AOH) enables controlled studies spanning fungal toxicity, CYP-mediated metabolism, apoptosis, and liver-fibrosis signaling. This practical workflow shows how to improve solvent handling, cell-based endpoint selection, comparative toxin design, and troubleshooting with a defined AOH research material.
-
Trichostatin A (TSA): From Target to Assay
2026-09-05
Trichostatin A (TSA) is a reversible HDAC inhibitor that connects chromatin acetylation with cancer-cell phenotypes. This guide focuses on designing interpretable assays, using breast and pancreatic cancer evidence to distinguish target engagement from therapeutic response.
-
Rotigotine hydrochloride in PD Research
2026-09-05
Build reproducible Parkinson’s disease research workflows around Rotigotine hydrochloride, from SH-SY5Y neuroprotection assays to route-controlled cystometry in 6-OHDA models. The key differentiator is its broad dopaminergic profile and the reference study’s demonstration that intravenous and subcutaneous exposure can produce distinct lower urinary tract outcomes.
-
Triamcinolone (B1859) Workflow Guide
2026-09-04
This practical guide explains how to prepare, store, and quality-control Triamcinolone for controlled studies of glucocorticoid receptor signaling, inflammation, and immunosuppression. It is intended for scientific research workflows only and should not be used for diagnostic, therapeutic, or clinical applications.
-
Palonosetron for Chemotherapy-Induced Nausea and Vomiting
2026-09-04
The Ruhlmann and Herrstedt review explains why palonosetron differs pharmacologically from earlier 5-HT3 receptor antagonists, emphasizing its long half-life, high receptor affinity, allosteric binding, and positive cooperativity. Its practical contribution is a careful comparison of preclinical and clinical evidence, particularly the possibility of improving control during the difficult delayed phase of chemotherapy-induced nausea and vomiting.
-
ABT-737: A BCL-2 Protein Inhibitor Workflow
2026-09-03
ABT-737 provides a defined mitochondrial apoptosis challenge for cancer-cell assays and a useful comparator when studying injury, senescence, and regeneration. This workflow connects its established oncology applications with a carefully bounded, hypothesis-generating use in biliary epithelial cell research.
-
Se-Methylselenocysteine Rewires PDAC Stress Responses
2026-09-02
This study identifies KYAT1-dependent metabolic activation and NRF2–ATF4 convergence as major determinants of how pancreatic ductal adenocarcinoma cells respond to Se-methylselenocysteine. Its integrated transcriptomic and functional analysis connects redox adaptation with ferroptosis-associated remodeling, while also showing substantial cell-line heterogeneity that may shape future biomarker-driven strategies.
-
TAK1–YAP Control of Gastric Cancer Stem Cells
2026-09-02
The reference study identifies TGFβ-activated kinase 1 (TAK1) as a driver of gastric cancer stem-cell self-renewal and tumor formation. Its central mechanistic finding is that interleukin-6 increases TAK1, which binds and stabilizes YAP, enabling SOX2 and SOX9 transcription and linking inflammatory signaling with gastric cancer stemness.
-
Site-Specific PEGylation of IL-11 in Pulmonary Fibrosis
2026-09-02
The reference study engineered receptor-biased interleukin-11 by introducing a site-specific cysteine and attaching polyethylene glycol at the GP130-binding interface. The optimized PEGylated analog preserved IL-11Rα interaction while reducing GP130 engagement, extended systemic exposure, and attenuated bleomycin-induced pulmonary fibrosis in mice.